A
Abdominal fat mass 186
Ablation treatments 123
Acarbose 199
Acetyl coenzyme A 29
Acid-labile subunit 232
Acinar 80
Acquired hypogonadotropic hypogonadism 102
Acquired immunodeficiency syndrome 165
Acquired lipodystrophy 254
and cardiovascular risk 240
clinical features of 196
diagnosis of 17
effect of treatment of 17
progresses 240
Activated protein kinase 29
Adenosine monophosphate 29
Adipocyte 99
hypertrophy 253
myocyte crosstalk 29
population 248
secrete several proinflammatory molecules 249
turnover 253
white and brown dofferemces 249t
Adipose-derived stem cells 262
biopsy 259
capacity, impaired 255
circadian rhythm 251
cytokines 112
deposits and their physiological function 248
distribution 254
in diabetes 262t
energy homeostat 250
extracellular matrix expansion 255
handling of acute nutrient flux 255
assessment of 256
clinical markers of 258
effect of antidiabetic agents on 260
radiological assessment of 258
structural and functional changes of 253
therapeutic strategies targeting 259
inadequate vascularization of 255
inflammation 255
insulin resistance 252
lipolysis 112
pathogenesis of insulin resistance 252fc
Adrenal axis, abnormalities in 236
Adrenal cortical physiology in diabetes, changes in 65
Adrenal disorders in diabetes, vigilance for 76
Adrenal tumor, surgical resection of 57
Adrenal-directed medical therapy 60
Adrenaline 73
Advanced glycation end-products, formation of 266
Aging males’ symptoms rating scale 104
Alcohol 157
Aldactone, evaluation study 67
Alkaline phosphatase 272
Alpha-glucosidase inhibitors 94
Alpha-interferon 194
Alpha-melanocyte-stimulating hormone 109
Amblyopia 142
Amelioration of thyrotoxicosis 38
American Association of Pediatrics 175
Amino acidemia 176
Amino acids 200
Amiodarone 239
Amiodarone-induced thyrotoxicosis 240
Amlexanox 263
Anakinra 261
Androgen
deficiency 99
in aging males 104
deprivation therapy 99
for prostate cancer 101
excess in females 111f
on female metabolism, effects of 110
receptor 111
replacement therapy 285
compliance of 101
Androstenedione 56
Angiosarcoma 15
Angiotensin II receptor blockers 167
Angular cheilitis 202
Antepartum pituitary necrosis 239
Anthropometric measures 256
Antidiabetic medications, effect on 50t
Antihypertensive agents 166
Anti-inflammatory agents 42
Antithyroid peroxidase 31
Aortic root abnormalities 142
Apoptosis 253
Artifactual hypoglycemia 149
Atherogenic dyslipidemia 278
Atherosclerosis 251
Auditory system 142
Autoimmune hemolytic anemia 143
Autoimmune hypoglycemia 152
Autonomic nervous system 71
Autonomic neuropathy culminates 93
Axonal sensory neuropathy 142
B
Basal bolus insulin therapy 63
Bathmotropic 72
Beckwith–Wiedemann syndrome 176
Beige adipocytes 249
Beta-adrenergic agonists 165
Bicuspid aortic valve 142
Bile salt-dependent lipase 93
Biliopancreatic diversion 261
Bioimpedance absorptiometry 258
Birth asphyxia 177
Birth weight, very-low 179
Blood-brain barrier 22
Blood-to-brain transport 208
Body composition 270
Body fat distribution, regulation of 110
Body weight 257
Bone
disease 45
high-turnover 235
low-turnover 236
formation 274
health
effect of vitamin D 271
in diabetes 265
factors leading to impaired 266
factors leading to impaired 268
interpretation 269
metabolism parameters 51
mineral health 51
mineral homeostasis 235
resorption, markers of 274
specific factors 274
turnover markers 48
Brain regions, diversity of 13
Brain-derived neurotrophic factor 15
Brainstem structures 13
Breast cancers 221
Bromocriptine quick release 21
Bronchial carcinoids 199
Brushfield iris spots 142
C
Calcium 42
Calcium and phosphate 265
Calcium-channel blockers 167
Canagliflozin 224
Capillary density 240
Carboxyl ester lipase 136
Carboxylase 29
Cardiac rhythm abnormalities 241
Cardiomyocyte hypertrophy 240
Cardiomyopathy 241
Cardiovascular events 67
Cardiovascular function 72
Cardiovascular risk for primary hyperaldosteronism 242
Cardiovascular system 142
Carnitine deficiency 176
Carotid intima-media thickness 241
Carpal tunnel syndrome 196
Catabolic phase 112
Catalytic conversion of glycogen 4
deficiency 155
derivatives 262
excess 155
increase heart rate 72
induced cardiomyopathy 241
levels 175
pharmacological use of 76
producing tumors 241
regulate glucose 72
secreting tumors 74
Celiac disease 143
Cell, types of islets 80
Central glucose sensing, molecular mechanisms of 12
Ceramides 252
Cerebellar ataxia 142
Cerebral aneurysm 15
Cesarean section for fetal distress 177
Cholesteatoma 15
Chordoma 15
Chorea 142
Chronotropic 72
Circulating glucose 83
Coarse facies 196
Cocaine-amphetamine regulated transcript 15
Cognitive behavioral therapy 281
Combined oral contraceptives 165
Complex syndrome 5
Conduction defects 142
Consortium for study of chronic pancreatitis 94
Continuous glucose monitoring 218
Continuous subcutaneous insulin infusion 218
Contraception and diabetes 294
Cori disease 157
Coronary artery disease 239
Counter-regulatory hormone deficiency 153
Cranial nerve palsy 196
Cranial radiotherapy 15
Craniopharyngioma 15
and cardiovascular risk 241
clinical features of 198
clinical phenotype of diabetes in 57
glucovigilance in 59
management of hyperglycemia in 61
pathophysiology of secondary diabetes in 57
screening for 66
subclinical 57
Cyproterone acetate 116
Cytokine signaling, suppressor of 232
D
Daily living, activities of 188
Dead adipocytes promote insulin resistance 253
Debranching enzyme deficiency 157
Deficiency of phosphoenolpyruvate carboxykinase 157
Deficiency of pyruvate carboxylase 157
Dehydration, severe 187
Deoxyribonucleic acid 184
Diabetes 5
and hyperthyroidism 37t
and hypothalamus-pituitary-testicular axis 295
and metabolic syndrome 104
risk of 114
and spermatogenesis 296
clinical assessment of elderly 187
epidemiology of secondary diabetes 193
functional classification of elderly 188
in acromegaly, management of 18
in children and adolescents 181
in postmenopausal women 117
in Turner syndrome, screening for 116
in women with PCOS 115
in young, maturity onset 92
incidence of 24
management of fracture 49
bone turnover markers in 49t
classification of 194
fibrocalculous pancreatic 182
increased fracture risk in 267
monogenic 182
type 2 14, 27, 32, 33, 46, 48, 85, 99, 100, 105, 135, 153, 165, 182, 193, 204, 205, 218, 253, 278, 290, 292, 293
with unexplained hypoglycemia 66
Diabetes, pathogenesis of 193
Diabetes, specific factors 274
Diabetes, spectrum of 187
Diabetes, syndromes 7
Diabetes, treatment technologies 212
Diabetes, uncontrolled 65
Diabetes, underlying 201
Diabetic macrovascular disease 238
Diabetic vasculopathy 239
Diacylglycerol 252
Digestive enzymes 80
Disordered adipose tissue autophagy 256
Dopaminergic tone 21
Dorsal motor nucleus 13
Double collecting system 143
Drospirenone 116
Ductal adenocarcinoma 87
Dysglycemia 123
Dystonia 142
E
Empagliflozin 224
Endocardial cushion defects 142
Endocrine
cells, clusters of 80
component 80
underlying 194
drugs 162
beneficial effects on glucose metabolism 167
detrimental impact on glycemic control 163
on glucose homeostasis 162
dysfunction, treatment of 170
effects of drugs used for 239t
factors in diabetes 6
function 193
gland 112
metabolic milieu changes 174
pancreas activity 73
perspectives 204
Society Guidelines 104
therapy 8
effects of 162
vigilance in hypoglycemia 211
Endocrinology, canvas of 5
Endogenous glucose production, source of 83
Endometrial 221
Endometrial cancer 118
Endoplasmic reticulum stress 252
Endoscopic retrograde cholangiopancreatography 89
Endothelioma 15
Enhancer-binding protein alpha 248
Ependymoma 15
Epicanthal folds 142
Epidermoid 15
Epigenetic programming 184
Epithelial sodium channels 56
Eplerenone 67
Erectile dysfunction 282
diagnosis 283
epidemiology 282
etiopathogenesis 282
increased risk of 278
lifestyle modification 283
pharmacological treatment 283
Erythroblastosis fetalis 177
Estimated glomerular filtration rate 234
Estradiol 108
Ethanol 157
Euglycemia, maintaining 149
Euglycemic-hyperinsulinemic clamps 252
Exocrine antigens 93
Exocrine cells 80
Exocrine insufficiency 93
Exocrine pancreas, diabetes of 85
Exocrine pancreatic disorders 85
Exocrine pancreatic tissue 80
Exogenous glucocorticoid-induced diabetes 61
Exogenous insulin therapy 291
F
Farnesoid X receptor agonists 262
Fast oscillations 81
Fasting blood glucose 168
Fatty acid 200
Fecal chymotrypsin 89
Female reproductive function 112
Female sexual dysfunction 285
epidemiology 286
etiopathogenesis 286
treatment of 287
nonpharmacological 287
pharmacological 287
Fertilization 112
Fetal insulin secretion plays 174
Fibroblasts 248
Fibrocalculous pancreatic diabetes 90
Fibrosis and hypoxia 255
Folliculogenesis 112
Food intake and energy balance 109
Fracture risk
increased 48
Frank obesity 254
Free thyroid hormone levels 220
Functional androgen deficiency 99
G
Galactorrhea 196
Gallstone disease 251
Gamma knife radiotherapy 196
Ganglioneuroma 15
Gastrointestinal system 143
Gastrointestinal tract 291
Genetic
defects of
beta-cell function 194
insulin action 194
lipodystrophies 140
associated with diabetes 141
Genitourinary abnormalities 143
Geriatric diabetes 187
Germinoma 15
Glucagon deficiency 155
Glucagon dysfunction 7
Glucagon facilitates 83
Glucagon levels 207
Glucagonoma syndrome 202
Glucagon-producing tumors 201
deficiency states 176
effects of 54t
on glucose homeostasis 53
excess 20
exposure, long-term exogenous 64
growth hormone 3
Glucocorticoid-induced
diabetes, increased risk of 62
hyperglycemia management of 62
hyperglycemia minimizing 63
hyperglycemia risk of 61
Glucocorticoid-receptor antagonist 60
Glucocrinological
considerations hormone replacement therapy 118
considerations treatment in Turner syndrome 116
adrenal medulla 71
adrenals, new therapeutic avenues in 67
bidirectional relationship 4
concept of 161
expanding frontiers 5
framework 9
historical perspectives 4
neglected basics 5
new beginning 10
pancreas: historical perspectives 79
reproductive system: female 108
reproductive system: male 97
thyroid 27
Gluconeogenesis 83
Glucose and energy metabolism 28fc
Glucose brain of 76
Glucose counter-regulatory physiology 205
Glucose lipid profile 294
Glucose physiology 27
during pregnancy 112
in neonatal period 174
in relation to
adrenal cortex 53
bone mineral metabolism 42
female reproductive system 108
hypothalamus and pituitary 11
male reproductive system 98
pancreas 80
Glucose, regulator of 123
Glucose sensing by pancreas 81
Glucose-dependent insulinotropic peptide 255
Glucostatic theory 11
Glucovigilance in
across stages of life 174
childhood and adolescence 181
disorders of
adrenal cortex 56
adrenal medulla 74
female reproductive tract 113
during pregnancy 184
elderly 186
endocrine therapy 161
hypothalamic disorders 14
men with hyperprolactinemia 103
menopause 117
neonates 174
pancreatic disorders 85
pituitary disorders 15
reproductive period 183
thyroid disorders 29
Turner syndrome 116
vitamin D deficiency 45
Glycated hemoglobin 188
Glycemic
changes in 34
effect of dopamine agonists on 21
effects of therapeutic strategy on 59
optimization of 297
worsening of 37
during menstrual cycle 112
targets 212
Glycogen phosphorylase 157
Glycogen storage disorders 176
Glycogen synthase deficiency 157
Graves’ disease 30
Graves’ ophthalmopathy 38
Graves’ orbitopathy 38
Guanosine triphosphate 284
H
Hamartoma 15
Head trauma 15
Headache 196
Heart and estrogen 118
Hematological system 143
Hemodynamically stable 225
Heparin 210
Hepatic gluconeogenesis, increase 54
Hepatic insulin resistance 30
Hepatitis C virus 62
Hepatocyte nuclear factor 176
Hers disease 157
Hexokinase 176
Homeostatic model assessment of insulin resistance 293
Hormonal supplementation 123
Horseshoe kidney 143
Human immunodeficiency virus 165
Human leukocyte antigen 144
Human placental growth hormone 112
Hydrocortisone, formulations of 64
Hypercalcemia 242
Hypercalciuria 269
Hyperglucagonemia 93
and adverse pregnancy outcome 184
endovigilance in refractory 193
in neonates 178
causes of 179t
management of 75
pathogenesis of 58fc
prevalence of 89
related to chronic growth hormone 16f
screening for 59
uncontrolled 195
Hyperglycemic emergencies 38
Hyperglycemic hyperosmolar state 187
Hypermetabolic state 38
Hyperplasia 253
Hypertelorism 142
Hypertension 123
and cardiovascular risk 242
and diabetes 37
and thyrotoxicosis 154
clinical presentation of 201
leads 30
Hypertrophic cardiomyopathy 142
Hypertrophic obstructive cardiomyopathy 241
Hypertrophy 253
Hypoactive sexual desire disorder 280
Hypoestrogenism 232
approach to 158
causes 208
classification of 214
common causes of 151t
consider risk factors for 211
core element of 213
drugs useful in management of 170
evaluation of newborns for 177
elderly individuals 211
etiology of 209
impact of 208
improvement in insulin sensitivity 210
medical conditions 210
medications 209
pathophysiology of 206
treatment of 213
in endocrinopathies 148
incidence of 205
management of 177
neurogenic manifestations of 207
newborns at-risk for prolonged 177t
pathological causes of 151
prevention 204
severe 207
symptoms of 207
unawareness 169
impact of symptoms questionnaire 104
in males, treatment of 105
screening for 104
with diabetes, testing for 104
Hypoparathyroidism 47
Hypothalamic
arcuate nucleus 111
control of pancreatic function 13
dysfunction 15
gonadotropin-releasing hormone 111
nuclei
lateral 12
several 13
causes of 15
Hypothalamic-pituitary-adrenal, increased activation of 65
Hypothalamic-pituitary-ovarian 108
Hypothalamic-pituitary vigilance in diabetes 23
Hypotheses 92
I
Iatrogenic hypoglycemia 206
Immune mediated diabetes syndrome 136
Immune system, cells of 45
Immunoglobulin E 144
Inborn errors of metabolism 176
Incontinence, cerebellar ataxia 142
Inflammation and hyperparathyroidism 232
Inflammation, chronic 123
Inflammatory bowel disease 143
Inflammatory cells 248
Infliximab 263
Inotropic 72
Insulin gene 180
Insulin on bone, effects of 44
Insulin receptor gene mutation 176
Insulin receptoropathies 139
Insulin resistance syndrome 139
Insulin resistance worsening 252
Insulin-induced hypoglycemia 24
Insulin-regulated glucose transporter 98
Insulin-resistance syndrome 123
Intellectual disability 142
International Association of Diabetes and Pregnancy Study group 184
Interstitial fibrosis 240
Intestinal absorption 83
Intestinal lipase inhibitor 260
Intracellular accumulation 252
Intraurethral administration of prostaglandin 284
Intrauterine growth retardation 177
IPEX syndrome 143
Irregular pulsatile secretion 230
Irreversible myocardial damage 241
Isoforms of estrogen receptors 109
K
Ketogenesis, effect on 296
alterations in insulin/glucagon homeostasis 233
clinical manifestations 233
effect of 229t
endocrine function in 228t
gonadal axis abnormalities in women 231
mechanism of 228t
secondary diabetes due to endocrinopathies: effect on 237
supplementation with ergocalciferol 235
Kinetics of insulin secretion 81
L
Lactic acidosis, risk of 220
Laparoscopic adjustable gastric banding 261
Laurence–Moon-Biedl syndrome 194
Levothyroxine 30
Ligand 72
Lipogenesis, promotion of 218
Lipolysis 175
Lipolytic enzyme 136
Lipotoxicity 251
Litchi-associated seasonal toxic encephalopathy 157
Liver
and kidney diseases 155
gluconeogenesis 112
glucose output 3
injury 253
isoenzyme deficiency 157
Lorcaserin 8
Low libido 280
M
Macroglossia 196
Macronodular adrenocortical hyperplasia 199
Macrovascular complications 89
Male fertility, pathophysiological mechanisms of 296
Male sperm, fertility capacity of 296
Malnutrition 236
Mammalian target of rapamycin 98
Massachusetts male aging study questionnaire 104
Maternal plasma glucose 174
Mauriac syndrome 146
Meconium aspiration 177
Medicated urethral suppository for erections 284
Mediterranean-style diet 283
Medullary thyroid carcinoma, risk of 36
Megaloblastic anemia 143
Meglitinides 94
Melanin-concentrating hormone 12
Melanocyte-stimulating hormone 12
Meningioma 15
Menopausal hormonal therapy 118
Menorrhagia 291
Menstrual dysfunction 291
Menstruating women 183
Mesenchymal stem cells 248
Mesenchymal stem cells, apoptosis of 266
Metabolic and storage diseases 156
Metabolic diseases, management of 247
Metabolic disorders 251
Metabolic economy 254
Metabolic regulation 3
Metabolic signals 291
Metabolic storage diseases 157
and polycystic ovary syndrome: metabolic menace 131
criteria for 258
in endocrinopathy with hormone deficiencies 129
in endocrinopathy with hormone excess 128
PCOS overlap 131f
prevalence of 117
Metaiodobenzylguanidine scan 76
Methylene cyclopropyl glycine 157
Microarchitectural changes and bone strength 48
Micropenis 177
Mimic circadian rhythm 64
Mineral, crucial role in 265
Mitochondrial dysfunction 251
Mitogen-activated protein kinase 56
Mitotane 60
Mitral valves and myocardium 242
Mood stabilizers 15
Motor neuropathy 142
Muscle weakness, progressive 142
Mutations 180
Mutations, single-gene 15
Myoblasts 248
Myocardial steatosis 253
Myocellular fat 253
Myoclonus and dementia 142
Myocytes 99
Myokines 29
Myopathy 196
Myotonia 142
N
Naltrexone-bupropion 8
Naltrexone-bupropion sustained-release 260
National Cholesterol Education Program Adult Treatment Panel III 257
National Health and Nutrition Examination survey 32
National Institutes of Health 114
Necrolytic migratory erythema 202
Nesidioblastosis 151
Net catabolic state 112
Neurodegeneration 142
Neuroendocrine tumor 201
Neurogenic symptoms 207
Neuroglucoprivation 76
Neuroglycopenia, onset of 206
Neuroleptic malignant syndrome 225
Neuronal types 13
Neutropenia 143
Niacin 167
Nicotinamide adenine dinucleotide 156
Nitric oxide 13
Nocturnal hypoglycemia 63
Nonhyperinsulinemic hypoglycemia 156
Noninsulin pancreatogenous hypoglycemia syndrome 152
Nonislet cell tumor hypoglycemia 153
O
Oocyte maturation 291
Optic atrophy 142
Oral contraceptive 183
Organic aciduria 157
Organic androgen deficiency 99
Organomegaly 196
Orlistat 8
Osilodrostat 60
Osmotic symptoms 37
Osteokines in glucose homeostasis, role of 43
Osteovigilance in diabetes 47
Ovarian steroidogenesis regulation of 111
Overnight dexamethasone suppression test 57
Overt diabetes 185
Ovulatory dysfunction 112
Oxidation of guanine residues 297
Oxidative stress 252
P
Pancreatectomy 194
Pancreatic
alpha-cells 28
beta-cell function 28
effects on 110
risk of 93
cytokeratin 93
defects in pathogenesis of
diabetes 6
ducts 80
enzyme replacement therapy 89
fat 253
hormones 80
hypoplasia 179
injury 85
islets 28
lipase 80
vigilance in diabetes 91
Pancreatitis acute 85
Pancreatitis
acute, risk of diabetes 92
risk of diabetes 92
incidence of 222
recurrent 85
severe acute 87
with antidiabetic drugs, risk of 93
Paragangliomas 75
Paroxysmal atrial fibrillation 240
Paroxysmal supraventricular tachycardia 240
Peak bone mass 266
Pediatric endocrine society 175
Penile prosthetics 285
Penis, erectile tissue of 284
Peptide hormones of brain 5
Periaqueductal gray 13
Perinatal stress 177
Peripheral arterial disease 37
Peripheral nervous system 142
Peritoneal dialysis 156
Permanent neonatal diabetes mellitus, cases of 180
Persistent hyperinsulinemic hypoglycemia of infancy 158
Persistent hypoglycemia, management of 178
Phenylethanolamine N-methyltransferase 71
Pinealoma 15
Pituitary directed medical therapy 60
Pituitary disorders 14
Pituitary gonadotropin secretion 111
Pituitary in glucose regulation, role of 13
Pituitary macroadenoma 15
Pituitary tumors, treatment of 225
Plasma adrenocorticotropic hormone 236
Plasma c-peptide concentrations 158
Plasma membrane 73
Pluripotent stem cells 99
effect of 115
glucocrinological issues in management of 115
pathogenesis of 113
role of statins in 115
use of antidiabetic medications 115
Polyendocrinopathy 136
Polyglandular autoimmune endocrinopathy 7
Porphyria 142
Positron emission tomography 152
Postpartum care 295
Postprandial reactive hypoglycemia 153
Potassium 55
Potassium channel 180
Preadipocytes 248
Preconception period 294
Pregnancy and diabetes 294
Primary hyperparathyroidism 47
Progesterone 3
Progestogen only contraceptives 116
Prognathism 196
Propranolol 169
Proprotein convertase subtilisin 167
Prostate cancer 99
Psychotropic drugs 15
Ptosis 142
Puberty in men with diabetes 296
R
Radioactive iodine uptake 219
Radioiodine ablation 8
Random plasma glucose 185
Renal
and genitourinary system 143
cysts 143
dysfunction 143
dysfunction, progressive 143
failure, end-stage 236
impairment 234
Renin–angiotensin system 66
Retinal dystrophy 142
Retinoic acid 20
Rostral ventromedial medulla 77
Roux-en-Y gastric bypass 261
S
Salsalate 263
Sarcopenia 253
Sclerostin 44
Secrete pancreatic juices 80
Secretin-pancreozymin test 89
Selective estrogen receptor modulators 232
Sensorineural hearing loss 142
Serum thyroid-stimulating hormone 29
Serum trypsin measurement of 89
Sexual
arousal 104
aversion disorder 280
desire 280
diagnosis 281
epidemiology 280
etiopathogenesis 280
nonpharmacological treatment 281
pharmacological treatment 281
dysfunction 7
major risk factors for 278
in men with diabetes 280
response cycle 279
arousal/plateau 279
desire/excitement 279
orgasm 279
resolution 280
Sheehan's syndrome 153
Sick sinus syndrome 241
Sildenafil 283
Sinus tachycardia 241
Sitagliptin 223
Skin and musculoskeletal system 143
Sleep disturbances 196
Small heterodimer partner 50
Sodium 55
Sperm motility 184
Spironolactone 67
Statins 239
Steatohepatitis 143
Steatorrhoea 93
Stiff-man syndrome 142
Strabismus 142
Stroke-like episodes 142
Supraventricular tachycardia 241
Syndrome of inappropriate antidiuretic hormone 219
Syndromes associated with poor glycemic control 146
Syndromic obesity 167
T
Tactful glycemic control, principles of 212
Tadalafil 283
Teratoma 15
Testicular and erectile dysfunction 184
stimulate proliferator-activated receptor-gamma 38
Thrombocytopenia 143
Thyroglobulin 144
Thyroid
and arterial hypertension 125
and glucose intolerance 125
and lipid metabolism 124
and obesity 125
disease 32
associated with hypoglycemia 154
prevalence of 32
symptoms of 33
abnormalities 227
effect of metformin on 36
analogs 262
effect of 28
excess 201
on metabolic health, effect of 124
receptors 27
secretion of 240
peroxidase 144
Thyrotropin-releasing hormone 229
Thyrovigilance in diabetes 31
Thyroxine 229
Thyroxine-binding globulin 219
Tissue-specific effects on glycogen metabolism 55
Tissue transglutaminase 144
Toxic hypoglycemic encephalopathy 157
Toxic lipid metabolites 252
Trabecular bone score 275
Transient hyperglycemia 61
Transient hypoxia 175
Triglycerides, increased synthesis of 118
Trimethoprim sulfamethoxazole 210
Trypsinogen 80
Tumors 15
U
Ultradian oscillations 81
United Kingdom Prospective Diabetes study 218
United States Food and Drug Administration 168
Upper airway obstruction 196
Uremic toxins 236
Urinary metanephrine levels 75
V
Vacuum erection devices 284
Vardenafil 283
Ventromedial 109
Ventromedial nucleus 12
Visceral adipose tissue 248
Visceral adiposity index 258
Visfatin 249
Voltage-dependent calcium channels 82
Volumetric computed tomography 258
von Gierke disease 157